Triple-negative breast cancer (TNBC) is defined as a type of breast cancer deficient of expression of estrogen receptor (ER), progesterone receptor (PR), and HER2 protein and present a particularly challenging therapeutic target due to their highly invasive nature and relatively low response to therapeutics (Garrido-Castro et al., 2019). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.